These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 28935272)
1. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Moore KN; Tritchler D; Kaufman KM; Lankes H; Quinn MCJ; ; Van Le L; Berchuck A; Backes FJ; Tewari KS; Lee RB; Kesterson JP; Wenham RM; Armstrong DK; Krivak TC; Bookman MA; Birrer MJ Gynecol Oncol; 2017 Nov; 147(2):396-401. PubMed ID: 28935272 [TBL] [Abstract][Full Text] [Related]
2. Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. French JD; Johnatty SE; Lu Y; Beesley J; Gao B; Kalimutho M; Henderson MJ; Russell AJ; Kar S; Chen X; Hillman KM; Kaufmann S; Sivakumaran H; O'Reilly M; Wang C; Korbie DJ; ; ; Lambrechts D; Despierre E; Van Nieuwenhuysen E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching PA; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Pisterer J; Hillemanns P; Nakanishi T; Yatabe Y; Goodman MT; Lurie G; Matsuno RK; Thompson PJ; Pejovic T; Bean Y; Heitz F; Harter P; du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan JM; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut JM; Iversen E; Weber RP; Brennan D; Berchuck A; Pharoah P; Harnett P; Norris MD; Haber M; Goode EL; Lee JS; Khanna KK; Meyer KB; Chenevix-Trench G; deFazio A; Edwards SL; MacGregor S; Oncotarget; 2016 Feb; 7(6):6353-68. PubMed ID: 26840454 [TBL] [Abstract][Full Text] [Related]
3. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367 [TBL] [Abstract][Full Text] [Related]
4. Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. Krivak TC; Darcy KM; Tian C; Bookman M; Gallion H; Ambrosone CB; Deloia JA Gynecol Oncol; 2011 Jul; 122(1):121-6. PubMed ID: 21496891 [TBL] [Abstract][Full Text] [Related]
5. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198 [TBL] [Abstract][Full Text] [Related]
6. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study. Rubatt JM; Darcy KM; Tian C; Muggia F; Dhir R; Armstrong DK; Bookman MA; Niedernhofer LJ; Deloia J; Birrer M; Krivak TC Gynecol Oncol; 2012 May; 125(2):421-6. PubMed ID: 22261301 [TBL] [Abstract][Full Text] [Related]
7. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955 [TBL] [Abstract][Full Text] [Related]
8. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant? Lawson BC; Euscher ED; Bassett RL; Liu J; Ramalingam P; Zhong Y; Fleming ND; Malpica A Am J Surg Pathol; 2020 Feb; 44(2):206-213. PubMed ID: 31651523 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer. Suidan RS; Zhou Q; Iasonos A; O'Cearbhaill RE; Chi DS; Long Roche KC; Tanner EJ; Denesopolis J; Barakat RR; Zivanovic O Int J Gynecol Cancer; 2015 May; 25(4):599-606. PubMed ID: 25664437 [TBL] [Abstract][Full Text] [Related]
10. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899 [TBL] [Abstract][Full Text] [Related]
11. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP; J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. Grisham RN; Iyer G; Sala E; Zhou Q; Iasonos A; DeLair D; Hyman DM; Aghajanian C Int J Gynecol Cancer; 2014 Jul; 24(6):1010-4. PubMed ID: 24978709 [TBL] [Abstract][Full Text] [Related]
13. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Garcia-Soto AE; Java JJ; Nieves Neira W; Pearson JM; Cohn DE; Lele SB; Tewari KS; Walker JL; Alvarez Secord A; Armstrong DK; Copeland LJ Gynecol Oncol; 2016 Dec; 143(3):484-489. PubMed ID: 27726923 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study. Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869 [TBL] [Abstract][Full Text] [Related]